Tarsus (TARS) Q3 2026 Earnings Call Transcript
Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.
How this was made

The 30-second read
Why it matters
The raised guidance and high margins suggest a positive earnings surprise, likely supporting a price rally.
Market read
Earnings beat and guidance lift make TARS a near‑term trading candidate.
What to watch
Potential regulatory delays for pipeline assets or integration costs from recent acquisitions could temper growth.
Background
Tarsus Pharmaceuticals (TARS) held its Q3 2026 earnings call, presenting sales figures and updated guidance.
Ticker impact
Q3 2026 earnings call disclosed $194.6M net product sales and raised full‑year guidance to $715‑$730M.
potential upside as the market prices in higher guidance and robust margins
Guidance beat prior expectations and gross margin remains high at ~93%, supporting a bullish view.
Market effects
Eye‑care and ophthalmology sector may see broader optimism on demodex treatment demand.
U.S. biotech and specialty pharma stocks could benefit from the upbeat outlook.
Limited to markets tracking U.S. biotech earnings.
Counterpoint
If the market had already priced in strong growth, the guidance raise may be already baked in, limiting upside.
Key entities
- CompanyTarsus Pharmaceuticals
US‑listed biotech focused on ocular therapies.

